Payment overview · 2025
General Payments
$1,247.94
47 reported records · 25 companies
Healthcare provider profile · identity verified
Sun Ik Kim, MD
Allopathic & Osteopathic Physicians|Urology · SAN BERNARDINO, CA · NPI 1093738932
Verified facts
What the public records show
CMS Open Payments records show Sun Ik Kim, MD received $1,247.94 in general payments during 2025 across 47 reported records.
Sumitomo Pharma America, Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Lupron Depot, Orgovyx, Trelstar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Lupron Depot by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Orgovyx by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Gemtesa by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 17129 records involving 6223 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Orgovyx by this doctor in 2024.
Verity Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Trelstar as an associated drug or biological on 2410 records involving 1349 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelstar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $200.84 | 16.1% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $150.43 | 12.1% | 5 | 2025 |
| Dornier MedTech America, Inc | Unresolved — no canonical attribution shown | $105.10 | 8.4% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $75.48 | 6.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.17 | 5.7% | 4 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.23 | 5.3% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $60.94 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.22 | 4.3% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $51.04 | 4.1% | 2 | 2025 |
| UROGEN PHARMA, INC. | Unresolved — no canonical attribution shown | $46.07 | 3.7% | 1 | 2025 |
| Blue Earth Diagnostics | Unresolved — no canonical attribution shown | $36.57 | 2.9% | 1 | 2025 |
| Agiliti Surgical, Inc. | Unresolved — no canonical attribution shown | $35.63 | 2.9% | 1 | 2025 |
| Procept Biorobotics Corporation | Unresolved — no canonical attribution shown | $28.14 | 2.2% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $27.74 | 2.2% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $25.75 | 2.1% | 1 | 2025 |
| Calyxo, Inc. | Unresolved — no canonical attribution shown | $25.37 | 2.0% | 1 | 2025 |
| BIOPROTECT MEDICAL, INC. | Unresolved — no canonical attribution shown | $24.69 | 2.0% | 1 | 2025 |
| IMMUNITYBIO, INC. | Unresolved — no canonical attribution shown | $23.88 | 1.9% | 1 | 2025 |
| ACCORD HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $23.54 | 1.9% | 1 | 2025 |
| Myriad Genetic Laboratories, Inc. | Unresolved — no canonical attribution shown | $22.61 | 1.8% | 1 | 2025 |
| C. R. Bard, Inc. & Subsidiaries | Unresolved — no canonical attribution shown | $21.74 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.09 | 1.7% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $20.57 | 1.6% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $16.03 | 1.3% | 1 | 2025 |
| DENTSPLY IH AB | Unresolved — no canonical attribution shown | $14.07 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,243.09 | 46 |
| Education | $4.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $200.84 | 10 | 2025 |
Source payment records
|
|||||
| Dornier MedTech Normalized: dornier medtech |
Device | Dornier MedTech America, Inc | $105.10 | 1 | 2025 |
Source payment records
|
|||||
| SpaceOAR System Normalized: spaceoar system |
Device | Boston Scientific Corporation | $102.65 | 2 | 2025 |
Source payment records
|
|||||
| Trelstar Normalized: trelstar |
Drug | Verity Pharmaceuticals Inc. | $66.23 | 3 | 2025 |
Source payment records
|
|||||
| FLOSEAL Normalized: floseal |
Biological | Baxter Healthcare | $60.94 | 1 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $56.98 | 2 | 2025 |
Source payment records
|
|||||
| LUPRON DEPOT Normalized: lupron depot |
Drug | ABBVIE INC. | $54.09 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $53.22 | 2 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $53.22 | 2 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $53.22 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $51.04 | 2 | 2025 |
Source payment records
|
|||||
| JELMYTO Normalized: jelmyto |
Drug | UROGEN PHARMA, INC. | $46.07 | 1 | 2025 |
Source payment records
|
|||||
| Bulkamid Normalized: bulkamid |
Device | Boston Scientific Corporation | $38.20 | 1 | 2025 |
Source payment records
|
|||||
| POSLUMA Normalized: posluma |
Drug | Blue Earth Diagnostics | $36.57 | 1 | 2025 |
Source payment records
|
|||||
| Koelis Trinity MRI/US Fusion Normalized: koelis trinity mri us fusion |
Device | Agiliti Surgical, Inc. | $35.63 | 1 | 2025 |
Source payment records
|
|||||
| Sonablate HIFU Normalized: sonablate hifu |
Device | Agiliti Surgical, Inc. | $35.63 | 1 | 2025 |
Source payment records
|
|||||
| AQUABEAM ROBOTIC SYSTEM Normalized: aquabeam robotic system |
Device | Procept Biorobotics Corporation | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| CVAC ASPIRATION SYSTEM Normalized: cvac aspiration system |
Device | Calyxo, Inc. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| BIOPROTECT BALLOON IMPLANT SYSTEM Normalized: bioprotect balloon implant system |
Device | BIOPROTECT MEDICAL, INC. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| ANKTIVA Normalized: anktiva |
Drug | IMMUNITYBIO, INC. | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| Camcevi Normalized: camcevi |
Drug | ACCORD HEALTHCARE, INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| PROLARIS Normalized: prolaris |
Device | Myriad Genetic Laboratories, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| Aptra Normalized: aptra |
Device | C. R. Bard, Inc. & Subsidiaries | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| NANOKNIFE Normalized: nanoknife |
Device | AngioDynamics, Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| CURE CATHETER Normalized: cure catheter |
Device | ConvaTec Inc. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| LOFRIC Normalized: lofric |
Device | DENTSPLY IH AB | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $9.58 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 147 | exact normalized | Medicare Part D |
| LUPRON DEPOT lupron depot |
2025 | Lupron Depot | 2024 | 88 | exact normalized | Medicare Part D |
| ORGOVYX orgovyx |
2025 | Orgovyx | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Trelstar trelstar |
2025 | Trelstar | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
88 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
147 | 41 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 17129 supporting records · 6223 recipient NPIs · example record 1176593507 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Verity Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Trelstar open payments reported associated product |
CMS Open Payments — General Payments 2410 supporting records · 1349 recipient NPIs · example record 1234194651 |
Trelstar · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamsulosin Hcl | Tamsulosin Hcl | 2130 | 706 |
| Finasteride | Finasteride | 1763 | 550 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 587 | 477 |
| Myrbetriq | Mirabegron | 571 | 174 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 505 | 190 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 333 | 272 |
| Sildenafil Citrate | Sildenafil Citrate | 293 | 91 |
| Cephalexin | Cephalexin | 282 | 128 |
| Doxazosin Mesylate | Doxazosin Mesylate | 261 | 65 |
| Gemtesa | Vibegron | 147 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 103 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 96 | 78 |
| Lupron Depot | Leuprolide Acetate | 88 | 38 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 74 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 23 |
| Bicalutamide | Bicalutamide | 52 | 18 |
| Trelstar | Triptorelin Pamoate | 49 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | suppressed |
| Dutasteride | Dutasteride | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 31 |
| Potassium Citrate Er | Potassium Citrate | 36 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 15 |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 30 | 29 |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Trimethoprim | Trimethoprim | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Tadalafil | Tadalafil | 20 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Orgovyx | Relugolix | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Eligard | Leuprolide Acetate | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 13 | 12 |
| Testosterone | Testosterone | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,247.94 · 47 records | Sumitomo Pharma America, Inc. | AMS 700, ANKTIVA, AQUABEAM ROBOTIC SYSTEM, AVYCAZ, Aptra, BARRIGEL, BIOPROTECT BALLOON IMPLANT SYSTEM, Bulkamid, CURE CATHETER, CVAC ASPIRATION SYSTEM, Camcevi, Dornier MedTech, ERLEADA, FLOSEAL, GEMTESA, JELMYTO, Koelis Trinity MRI/US Fusion, LOFRIC, LUPRON DEPOT, MI CANCER SEEK, NANOKNIFE, ORGOVYX, PLUVICTO, POSLUMA, PROLARIS, STRATAFIX, Sonablate HIFU, SpaceOAR System, TALZENNA, Trelstar, UROLIFT, XTANDI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error